Pulse Biosciences, Inc. announced enhancements to its executive leadership team to support its next pivotal phase of growth. Proven atrial fibrillation medical technology leader Burke T. Barrett has been appointed President effective immediately. Concurrently, the Company announced the appointment of Kevin Danahy, former President and Chief Executive Officer, as Chief Commercial Officer.

Mr. Danahy will now focus his full time leading the pilot launch of the recently FDA cleared CellFX nsPFA Percutaneous Electrode System. Mr. Barrett is a hands-on leader and executive with more than 35 years of experience building teams that bring novel, complex medical devices from concept, through design validation, clinical studies, regulatory approvals, and manufacturing scale-up to commercialization. During his eighteen years at CardioFocus, Inc., Burke held a number of positions of increasing responsibility and was part of the team that built a pioneering electrophysiology ablation device and a global commercial company, departing as CEO and President.

Previously, he was part of the teams that successfully took two companies public, Biofield Corp. and Cyberkinetics Neurotechnology Systems, Inc., and has been an officer of two public companies ? Cyberonics, Inc., as Vice President of Business and Technology Development, and Cyberkinetics, as Vice President of Clinical Operations.

Mr. Barrett was also an active member of the FDA?s Circulatory System Medical Devices Advisory Panel for four years. Currently, he sits on the Board of Directors of VDI Technologies. Mr. Barrett holds Bachelor?s degrees in Chemistry and Chemical Engineering from Syracuse University and a Masters in Business Administration from Kennesaw State University.